Gouty Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx.
| Published date | 17 April 2024 |
M2 PRESSWIRE-April 17, 2024-: Gouty Arthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx
(C)1994-2024 M2 COMMUNICATIONS
RDATE:16042024
The Gouty Arthritis Market Forecast report offers an in-depth understanding of the Gouty Arthritis, historical and forecasted epidemiology as well as the Gouty Arthritis market trends in the 7MM.
DelveInsight's "Gouty Arthritis Market Insights, Epidemiology, and Market Forecast-2032'' report offers an in-depth understanding of the Gouty Arthritis, historical and forecasted epidemiology as well as the Gouty Arthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Gouty Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gouty Arthritis Market Forecast
Some of the key facts of the Gouty Arthritis Market Report:
*The Gouty Arthritis market size is estimated to grow at a significant CAGR during the study period (2019-2032) *In October 2023, Atom Bioscience, a biotechnology firm based in China, has administered the initial dose to the first patient in a Phase IIb/III clinical trial of ABP-671 for the treatment of chronic gout, a prevalent form of inflammatory arthritis. This randomized, multi-center, double-blind study aims to enroll 580 patients from the United States and other countries. *In October 2023, Selecta Biosciences, Inc. has announced an agreement to transfer the manufacturing and development rights, along with the remaining clinical operations, of ImmTOR for SEL-212 to its partner in development and commercialization, Swedish Orphan Biovitrum AB (publ.) (Sobi). Effective November 6, 2023, Sobi will assume responsibility for manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is being developed for the treatment of chronic refractory gout. *Over 1.2 million cases of Gouty Arthritis were reported to be prevalent in the 7MM in 2021, with the United States reporting the largest number of cases. *There were over 241,000 Gouty Arthritis cases diagnosed in the US in 2021, and over 460,000 cases in the EU-5. During the projected period (2022-2032), there is expected to be an increase in these numbers. *Gouty Arthritis affected women more than it...
To continue reading
Request your trial